Country: Ирска
Језик: Енглески
Извор: HPRA (Health Products Regulatory Authority)
Fenbendazole
Intervet Ireland Limited
QP52AC13
Fenbendazole
18.75 percent weight/weight
Oral paste
POM: Prescription Only Medicine as defined in relevant national legislation
Horses
fenbendazole
Endoparasiticide
Authorised
1999-10-01
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Panacur Equine Oral Paste 18.75 %w/w 2 QUALITATIVE AND QUANTITATIVE COMPOSITION For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Oral paste. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Horses and other equine species 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of immature and mature stages of nematodes of the gastro-intestinal tract of horses and other equine species. Sensitive endoparasites include adult and immature stages of: Large and small strongyles Ascarids, _Oxyuris equi_ _Strongyloides_ spp. _Dictyocaulus arnfeldi_ Panacur is effective for the treatment of immature and migrating strongyle infections in equines. 4.3 CONTRAINDICATIONS Do not use in animals with known hypersensitivity to the active ingredient. Each g paste contains: ACTIVE SUBSTANCE Fenbendazole 187.5 mg EXCIPIENTS Methyl Parahydroxybenzoate 1.7 mg Propyl Parahydroxybenzoate 0.16 mg I R I S H M E D I C I N E S B O A R D ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _2_ _2_ _/_ _0_ _7_ _/_ _2_ _0_ _1_ _1_ _C_ _R_ _N_ _ _ _7_ _0_ _1_ _0_ _1_ _5_ _8_ _p_ _a_ _g_ _e_ _ _ _n_ _u_ _m_ _b_ _e_ _r_ _:_ _ _ _1_ 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy: - Too frequent and repeated use of anthelmintics from the same class, over an extended period of time. - Underdosing, which may be due to unde Прочитајте комплетан документ